Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Baclofen
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Allos Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
Allos Pharma Acquires Global Rights to Arbaclofen and Grant Award
Details : Allos has secured worldwide rights to arbaclofen, a selective GABA-B receptor agonist previously evaluated in multiple Phase II and III trials in ASD, Fragile X syndrome and 16p11.2 deletion syndrome.
Product Name : STX209
Product Type : Miscellaneous
Upfront Cash : Undisclosed
August 21, 2025
Lead Product(s) : Baclofen
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Allos Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Baclofen
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Allos Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Allos Pharma Secures Exclusive License on Arbaclofen in Fragile X Syndrome
Details : Arbaclofen is the active enantiomer of baclofen, a GABA-B receptor agonist. Statistically significant and clinically meaningful efficacy was observed in a prior Phase 3 trial conducted by Seaside Therapeutics in humans with Fragile X Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
November 19, 2020
Lead Product(s) : Baclofen
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Allos Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders
Details : Arbaclofen is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Autism Spectrum Disorder.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 15, 2012
Lead Product(s) : Baclofen
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
An Open Label Extension Study in Subjects With Fragile X Syndrome
Details : Arbaclofen is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Fragile X Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 15, 2012
Lead Product(s) : Baclofen
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : STX107
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Assess the Tolerability of a Single Dose of STX107 in Adults With Fragile X Syndrome
Details : STX107 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Fragile X Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 30, 2011
Lead Product(s) : STX107
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Baclofen
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Arbaclofen is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Fragile X Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 29, 2011
Lead Product(s) : Baclofen
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Arbaclofen is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Autism Spectrum Disorder.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 02, 2011
Lead Product(s) : Baclofen
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Arbaclofen is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Fragile X Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 24, 2011
Lead Product(s) : Baclofen
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
An Open Label Extension Study of STX209 in Subjects With Autism Spectrum Disorders
Details : Arbaclofen is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Autism Spectrum Disorder.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 09, 2010
Reset All
